Integration of apolipoprotein B into the SCORE2 framework: implications for cardiovascular risk prediction

被引:0
|
作者
Wong, Wen Kai [1 ,2 ,3 ]
Takeuchi, Fumihiko [1 ,4 ,5 ]
Thao, Le Thi Phuong [6 ]
Nicholls, Stephen J. [7 ,8 ]
Chew, Derek P. [7 ,8 ]
Peter, Karlheinz [1 ,2 ]
机构
[1] Univ Melbourne, Fac Med Dent & Hlth Sci, Grattan St, Parkville, Vic 3010, Australia
[2] Baker Heart & Diabet Inst, Atherothrombosis & Vasc Biol Lab, 75 Commercial Rd, Melbourne, Vic 3004, Australia
[3] Imperial Coll London, Fac Med, London, England
[4] Baker Heart & Diabet Inst, Syst Genom Lab, Melbourne, Australia
[5] Baker Heart & Diabet Inst, Cambridge Baker Syst Genom Initiat, Melbourne, Australia
[6] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Australia
[7] Monash Univ, Victorian Heart Inst, Melbourne, Australia
[8] Monash Hlth, Victorian Heart Hosp, Melbourne, Australia
基金
英国医学研究理事会;
关键词
Apolipoprotein B (ApoB); Systematic Coronary Risk Evaluation 2 (SCORE2); Cardiovascular risk prediction; UK Biobank; CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; LDL-CHOLESTEROL; I RATIO; A-I; PREVENTION; GUIDELINES; MANAGEMENT; SOCIETY; MARKERS;
D O I
10.1093/eurjpc/zwaf039
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To evaluate whether integrating Apolipoprotein B (ApoB) into the Systematic Coronary Risk Evaluation 2 (SCORE2) cardiovascular risk prediction framework improves its predictive accuracy and clinical applicability within the UK Biobank population. Methods and results A 10-year prospective cohort study was conducted with 448 303 UK Biobank participants eligible for SCORE2 calculation. Three approaches were employed: (i) threshold analysis to determine the optimal ApoB cutoff for cardiovascular disease (CVD) risk prediction using Youden's Index, (ii) assessment of the synergistic effect of SCORE2 and ApoB through concordant and discordant classifications, and (iii) recalibration of the SCORE2 model by incorporating ApoB as an additional predictor. Each 0.2 g/L increase in ApoB was associated with an increased subdistribution hazard for CVD events [subdistribution hazard ratio (SHR): 1.13; 95% CI: 1.11-1.14, P < 0.001], accounting for non-cardiovascular death as a competing risk. Threshold analysis identified an optimal ApoB cutoff at 1.18 g/L; however, it demonstrated limited discriminatory performance (area under the curve 0.54), with low sensitivity (32.4%), and moderate specificity (74.4%). Individuals with both low ApoB (<1.18 g/L) and low SCORE2 risk (<5%) had a lower CVD incidence rate (232.51 per 100 000 person-years) compared with those identified as low risk by SCORE2 alone (253.69 per 100 000 person-years). Integration of ApoB into the SCORE2 model did not significantly improve the model discrimination, calibration, and net reclassification improvement. Conclusion Apolipoprotein B exhibited a dose-response relationship with cardiovascular risk but had limited standalone predictive utility within the UK Biobank population. However, combining ApoB with SCORE2 thresholds improved the identification of low-risk individuals, suggesting a complementary role for ApoB in refining cardiovascular risk stratification.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Apolipoprotein B in cardiovascular risk assessment
    Ahmad, Maud
    Sniderman, Allan D.
    Hegele, Robert A.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2023, 195 (33) : E1124 - E1124
  • [32] SCORE2 Screening Tool for Cardiovascular Risk Assessment in Psoriasis-A Case-Control Study
    Kampe, Tomas
    Baloghova, Janette
    Kolarcik, Peter
    Rimarova, Kvetoslava
    Dorko, Erik
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (11)
  • [33] Apolipoprotein B in the assessment of cardiovascular risk
    Ahmad, Maud
    Sniderman, Allan D.
    Hegele, Robert A.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2023, 195 (47) : E1644 - E1645
  • [34] APOLIPOPROTEIN-B AND CARDIOVASCULAR RISK
    CUVELIER, I
    STEINMETZ, J
    ANNALES DE BIOLOGIE CLINIQUE, 1982, 40 (04) : 440 - 440
  • [35] Validation of the SCORE2 risk prediction algorithm in a Portuguese population: A new model to estimate 10-year cardiovascular disease incidence in Europe
    Temtem, Margarida
    Mendonca, Maria Isabel
    Santos, Marina
    Sa, Debora
    Sousa, Francisco
    Freitas, Sonia
    Borges, Sofia
    Henriques, Eva
    Rodrigues, Mariana
    Soares, Carolina
    Rodrigues, Ricardo
    Serrao, Marco
    Drumond, Antonio
    Sousa, Ana Celia
    Reis, Roberto Palma
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2024, 43 (08) : 437 - 444
  • [36] Factors influencing Systemic Coronary Risk Estimation 2 (SCORE2)
    Gryglewska-Wawrzak, Katarzyna
    Banach, Maciej
    Sakowicz, Agata
    Sosnowska, Bozena
    Adach, Weronika
    Bielecka-Dabrowa, Agata
    CARDIOLOGY JOURNAL, 2025,
  • [37] The role of coronary artery calcium score and european score2 in primary prevention of cardiovascular disease
    Ferrante, G.
    Catapano, F.
    Bacallao, B.
    Romano, I
    Di Stefano, V
    Celata, A.
    Battaglia, V
    Carli, S.
    Del Monaco, G.
    Gioia, F.
    Amata, F.
    Latini, A.
    D'andrea, C.
    Francone, M.
    Condorelli, G.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [38] Estimation of 10-Year Cardiovascular Disease Risk in the Portuguese Population Using the Systematic Coronary Risk Evaluation 2 (SCORE2)
    Santos, Maria
    Sousa-uva, Mafalda
    Namorado, Sonia
    Goncalves, Teresa
    Matias Dias, Carlos
    Gaio, Vania
    ACTA MEDICA PORTUGUESA, 2024, 37 (10) : 720 - 724
  • [39] Flexible addition of risk modifiers on top of SCORE2 to improve long-term risk prediction in healthy individuals
    Auer, Johann
    Lamm, Gudrun
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 30 (15) : 1702 - 1704
  • [40] Replacing SCORE with SCORE2 in Portuguese primary care: News from the frontline of cardiovascular prevention
    Ferreira, Antonio Miguel
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2024, 43 (08) : 457 - 458